Prophylactic Enoxaparin Reduces Symptomatic Venous Thromboembolism Compared With No Chemoprophylaxis Within 95 Days After Knee Arthroscopy

The authors aimed to determine whether prophylactic administration of low-molecular-weight heparin (enoxaparin) after knee arthroscopy reduces the incidence of symptomatic venous thromboembolism (VTE) compared to no pharmacological prophylaxis. Their study found that enoxaparin significantly lowered the risk of symptomatic VTE within 95 days post-surgery, with a hazard ratio of 0.64, indicating a beneficial effect of the prophylactic treatment. Adverse events were infrequent in both groups, suggesting that enoxaparin is a safe option for VTE prevention in this patient population.